rituximab

obinutuzumab

catumaxomab

palivizumab

abciximab

alemtuzumab

adalimumab

infliximab

golimumab

certolizumab

basiliximab

daclizumab

trastuzumab

pertuzumab

cetuximab

panitumumab

natalizumab

vedolizumab

efalizumab

tocilizumab

ipilimumab

bevacizumab

ranibizumab

omalizumab

eculizumab

ustekinumab

siltuximab

sécukinumab

dénosumab

canakinumab

belimuman

Iode 131-tositumomab

ibritumomab tiuxetan

gemtuzumab ozogamycine

brentuximab vedotin

trastuzumab emtansine

EMD-273066

moxetumomab

stratégie ADEPT

abatacept